How Hyperbaric Oxygen Therapy May Reduce Rectal Bleeding and Support Healing After Pelvic Radiation
Radiation therapy is an important treatment for prostate, rectal, cervical, uterine, anal, bladder, and other pelvic cancers. Although modern radiation planning helps limit exposure to surrounding organs, part of the rectum may still receive radiation because of its proximity to the treatment field.
Some patients develop rectal symptoms during treatment, while others experience problems months or years after radiation has ended. Chronic radiation proctitis may cause rectal bleeding, urgency, mucus discharge, diarrhea, pain, tenesmus, fecal leakage, or difficulty controlling bowel movements. Severe cases can lead to anemia, repeated transfusions, ulceration, strictures, fistulas, or substantial disruption of daily life.
Hyperbaric oxygen therapy, commonly abbreviated as HBOT, may be considered for selected patients with persistent radiation-related rectal injury. Its purpose is not simply to cauterize a bleeding vessel. HBOT is intended to improve oxygen delivery within chronically hypoxic tissue and support vascular and mucosal repair.
Medicare generally recognizes radiation proctitis within the broader covered indication of soft tissue radionecrosis when HBOT is used as an adjunct to conventional treatment. Coverage requirements vary, and coverage alone does not determine whether treatment is medically appropriate for an individual patient. (Centers for Medicare & Medicaid Services)
Acute and Chronic Radiation Proctitis Are Different
Acute radiation proctitis develops during pelvic radiation or shortly after treatment. It primarily reflects injury to rapidly dividing cells within the rectal lining. Symptoms may include diarrhea, urgency, mucus discharge, rectal discomfort, and occasional bleeding.
These acute symptoms often improve after radiation is completed, although infection, medication effects, and other gastrointestinal conditions should still be considered.
Chronic radiation proctitis is a delayed tissue injury. It may appear months or years after radiation and can continue to evolve long after the original cancer treatment has ended. The delayed condition is driven less by temporary mucosal inflammation and more by progressive vascular damage, tissue hypoxia, fibrosis, and abnormal healing.
The American Society of Colon and Rectal Surgeons identifies rectal bleeding as the most common presentation of chronic radiation proctitis. Fecal urgency, tenesmus, and mucus drainage are also common. (ASCRS U)
Because the underlying biology differs, therapies used for acute symptoms are not necessarily effective for chronic radiation injury.
Why Irradiated Rectal Tissue Becomes Fragile
Radiation can damage the endothelial cells lining small blood vessels within the rectal wall. Over time, these vessels may narrow, thrombose, or disappear. The surrounding tissue receives less oxygen and fewer nutrients, limiting its ability to maintain a healthy mucosal surface.
The tissue may gradually develop:
- Reduced capillary density
- Chronic hypoxia
- Submucosal fibrosis
- Mucosal thinning and ulceration
- Fragile telangiectatic blood vessels
- Reduced elasticity and impaired healing
Telangiectasias are dilated, fragile vessels that can rupture when stool passes through the rectum. Bleeding may begin as an occasional streak of blood and progress to frequent hematochezia, clot passage, iron-deficiency anemia, or transfusion dependence.
Fibrosis and neuromuscular injury can also affect rectal compliance and bowel control. This helps explain why some patients experience urgency, frequent bowel movements, tenesmus, or incontinence even when bleeding is not the dominant symptom.
The injury is often diffuse rather than limited to one visible vessel. A focal endoscopic treatment may stop a particular bleeding point without fully correcting the hypoxic condition of the surrounding tissue.
How HBOT May Help Radiation Proctitis
During HBOT, the patient breathes oxygen while exposed to increased atmospheric pressure inside a medical hyperbaric chamber. The increased pressure raises arterial oxygen tension and substantially increases the amount of oxygen dissolved directly in plasma.
This oxygen-rich plasma can reach functioning vessels surrounding the irradiated area and create a stronger diffusion gradient into hypoxic tissue.
Repeated hyperbaric treatments may support:
- Increased oxygen delivery to damaged rectal tissue
- Angiogenic signaling and new capillary formation
- Fibroblast activity and collagen remodeling
- Repair of the rectal mucosal lining
- Modulation of chronic inflammatory activity
- Improved tissue resistance to recurrent injury
- Healing of selected radiation-associated ulcers
The immediate increase in tissue oxygen lasts for a limited period after each treatment. The longer-term goal is to stimulate structural repair, particularly the development of a more functional microvascular supply.
The American Society of Colon and Rectal Surgeons recommends HBOT as an effective option for reducing bleeding in chronic radiation proctitis. The recommendation is classified as strong and based on moderate-quality evidence. (ASCRS U)
Rectal Bleeding After Radiation Requires Evaluation
A history of pelvic radiation does not mean that every episode of rectal bleeding is caused by radiation proctitis.
Other possible causes include:
- Recurrent or new colorectal malignancy
- Hemorrhoids
- Anal fissures
- Diverticular bleeding
- Inflammatory bowel disease
- Ischemic or infectious colitis
- Angiodysplasia
- Colorectal polyps
- Medication-related bleeding
The evaluation should document the amount, duration, and frequency of bleeding, along with bowel urgency, mucus discharge, pain, tenesmus, continence changes, weight loss, medication use, and the patient’s original cancer history.
At minimum, ASCRS recommends a disease-specific history, physical examination, digital rectal examination, and proctoscopic evaluation. Colonoscopy may be required when the full extent of disease cannot be determined, another form of colitis must be excluded, or the patient is due for colorectal cancer evaluation. (ASCRS U)
Laboratory assessment may include a complete blood count, iron studies, metabolic testing, and coagulation evaluation when bleeding is clinically significant.
The objective is not merely to confirm that radiation changes are present. It is to determine whether those changes explain the symptoms and whether another condition requires treatment.
Conventional Treatment Usually Precedes HBOT
Management depends on the severity and dominant symptoms. Mild bleeding may be observed or treated medically, while persistent hemorrhage may require endoscopic intervention.
Therapies used in chronic radiation proctitis include:
- Sucralfate retention enemas
- Formalin application
- Argon plasma coagulation
- Correction of iron deficiency or anemia
- Treatment of diarrhea and bowel dysfunction
- Dietary modification when clinically appropriate
- Review of anticoagulant or antiplatelet therapy
- HBOT for selected refractory or diffuse disease
ASCRS considers sucralfate retention enemas moderately effective for rectal bleeding. Formalin application and argon plasma coagulation are also recognized treatments for hemorrhagic chronic radiation proctitis. (ASCRS U)
Argon plasma coagulation, commonly called APC, is frequently used when telangiectatic vessels can be treated endoscopically. ASCRS reports that APC produces cessation or a meaningful reduction in bleeding in many treated patients, although more than one session may be required. Rectal pain, mucus discharge, and ulceration may occur after treatment, while strictures and fistulas are less common but important complications. (ASCRS U)
HBOT may be particularly relevant when:
- Bleeding persists after medical or endoscopic treatment
- Radiation injury is extensive or diffuse
- Repeated cauterization could increase tissue damage
- Rectal ulceration accompanies the bleeding
- The patient has multiple pelvic radiation injuries
- A tissue-restorative approach is preferred before more invasive surgery
The sequence should be individualized. Not every patient needs to undergo every available medical and endoscopic therapy before receiving a hyperbaric consultation.
Which Patients May Be Considered for HBOT?
Potential candidates include patients with documented delayed radiation injury who continue to experience clinically meaningful symptoms despite appropriate evaluation and conventional management.
Reasons for referral may include:
- Persistent or recurrent hematochezia
- Iron-deficiency anemia caused by ongoing rectal bleeding
- Repeated blood transfusions or iron infusions
- Failure or recurrence after endoscopic therapy
- Radiation-associated rectal ulceration
- Chronic urgency, pain, tenesmus, or mucus discharge
- Diffuse tissue injury that is difficult to treat focally
- Concern about progression to more destructive interventions
- Concurrent radiation cystitis or other pelvic soft tissue injury
The patient’s overall cancer status should be reviewed. HBOT treats delayed radiation tissue injury, not the malignancy itself. New bleeding, pain, unexplained weight loss, obstruction, or suspicious endoscopic findings require appropriate oncologic and colorectal evaluation.
A patient is less likely to benefit when symptoms are primarily caused by a fixed mechanical problem, untreated malignancy, severe stricture, established fistula, active inflammatory bowel disease, or another condition that requires a different intervention.
What an HBOT Course May Involve
The treatment protocol is prescribed by a hyperbaric physician after review of the radiation history, endoscopic findings, previous treatments, current symptoms, and medical risks.
A typical course may involve:
- Treatment five days per week
- Approximately 30 to 40 sessions
- Pressure commonly between 2.0 and 2.5 atmospheres absolute
- Around 80 to 90 minutes of oxygen exposure at treatment pressure
- Air breaks when included in the prescribed protocol
Protocols vary, and additional sessions may be considered when the patient is improving but has not reached the treatment objective.
The randomized Clarke trial used oxygen at 2.0 ATA and followed patients for as long as five years. The HOT2 trial used 40 exposures at 2.4 ATA, with 90-minute sessions delivered five days per week over eight weeks. (ASCRS U)
During the course, clinicians should monitor:
- Frequency and volume of rectal bleeding
- Hemoglobin and iron status
- Transfusion or iron-replacement requirements
- Stool frequency
- Fecal urgency and continence
- Rectal pain and tenesmus
- Treatment tolerance
- Need for additional endoscopic or surgical care
Improvement may occur during treatment, but tissue remodeling can continue after the final session. Patients should understand that HBOT is generally not an immediate hemostatic procedure.
What the Evidence Shows
Clinical evidence for HBOT in chronic radiation proctitis is supportive but not uniform.
A randomized, double-blind crossover trial led by Clarke evaluated patients with refractory radiation proctitis. Among evaluable participants, the HBOT group demonstrated greater improvement and a higher responder rate than the control group. The investigators reported an absolute risk reduction of 32 percent and a number needed to treat of approximately three after the initial treatment allocation. (PubMed)
Observational studies summarized by ASCRS have also reported reductions in bleeding, diarrhea, rectal pain, urgency, and endoscopic ulceration. Treatment courses in these reports commonly involved approximately 36 to 40 sessions, although patient selection and outcome definitions varied. (ASCRS U)
The HOT2 trial produced a different result. This double-blind, sham-controlled phase 3 trial enrolled 84 patients with chronic gastrointestinal symptoms after pelvic radiation. At 12 months, investigators found no statistically significant benefit in the primary bowel-function outcome or rectal-bleeding score. (PubMed)
The trials studied related but not identical clinical populations and used different eligibility criteria, endpoints, treatment pressures, and methods of measuring response. These differences may partly explain the conflicting results, but they do not eliminate the uncertainty.
The evidence supports a selective rather than universal approach. HBOT should not be presented as an effective treatment for every chronic bowel symptom following radiation. Its strongest clinical rationale is generally in well-characterized delayed radiation tissue injury, particularly persistent bleeding or ulcerative proctopathy that has not responded adequately to conventional care.
Risks and Contraindications of HBOT
HBOT is generally well tolerated in appropriately screened patients, but it has recognized risks.
Potential adverse effects include:
- Middle-ear or sinus barotrauma
- Temporary myopic vision changes
- Claustrophobia or confinement anxiety
- Pulmonary oxygen effects
- Blood glucose changes in patients with diabetes
- Rare oxygen-induced seizure
In the HOT2 trial, ear pain and refractive vision changes were among the more common treatment-associated events. (PubMed)
An untreated pneumothorax is generally considered an absolute contraindication. Pulmonary disease, difficulty equalizing ear pressure, seizure risk, unstable heart failure, implanted devices, and medication concerns require individualized review.
Patients with frequent diarrhea or fecal urgency may also worry about remaining in the chamber for the full treatment period. The hyperbaric team should discuss bowel timing, dietary triggers, medication schedules, and what will happen if a treatment must be stopped.
Surgery Is Reserved for Severe or Refractory Disease
Surgical intervention may become necessary when a patient develops uncontrolled bleeding, obstruction, severe stricture, fistula, perforation, necrosis, or symptoms that remain disabling despite less invasive treatment.
Possible procedures include fecal diversion, resection, reconstruction, or more extensive pelvic surgery. Operations in previously irradiated tissue carry increased risks because blood supply and healing capacity may already be compromised.
HBOT may sometimes be considered before a major operation or as part of a broader strategy to improve irradiated tissue, but it cannot reverse every structural complication. A mature fistula, fixed obstruction, or severely contracted segment may still require surgery.
The decision should involve colorectal surgery, gastroenterology, radiation oncology, hyperbaric medicine, and the patient. Preserving bowel function is important, but symptom control, cancer status, surgical risk, and quality of life must all be considered.
Measuring Meaningful Improvement
Complete cessation of rectal bleeding is an important goal, but it is not the only outcome that matters.
Meaningful improvement may include:
- Fewer bleeding episodes
- Reduced blood volume or clot passage
- Stabilization of hemoglobin
- Reduced need for transfusions or iron replacement
- Less urgency or tenesmus
- Improved continence
- Reduced rectal pain
- Fewer endoscopic procedures
- Greater confidence leaving home or returning to work
Radiation proctitis can profoundly affect dignity and independence. Patients may plan their days around restroom access, avoid travel, stop exercising, or withdraw socially because of bleeding and urgency.
These effects deserve the same clinical attention as endoscopic appearance. The most appropriate treatment plan should address tissue injury while recognizing the practical and emotional burden of living with unpredictable bowel symptoms.
HBOT offers a tissue-restorative option for selected patients with chronic radiation proctitis, particularly when bleeding or ulceration persists despite appropriate conventional treatment. It should be integrated into a multidisciplinary plan that confirms the diagnosis, excludes recurrent malignancy, treats anemia, addresses bowel dysfunction, and reserves invasive procedures for situations in which they are truly necessary.
